ea0028p242 | Pituitary | SFEBES2012
Parry Heather
, Thorpe Alice
, Wilkinson Ian
, Pradnanhanga Sarbendra
, Sayers Jon
, Artymiuk Peter
, Ross Richard
Background: The development of recombinant biologics such as interferon, insulin and Growth Hormone (GH) has had a major impact on the management of diseases including hepatitis, diabetes and GH-deficiency. However, most biologics undergo rapid renal filtration and proteolytic degradation, necessitating frequent dosing regimens. Pegylation can successfully delay clearance but has several drawbacks including potential toxicity, expense and reduced activity. There is therefore n...